Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Rhea-AI Summary

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical firm, targets therapies for nonalcoholic steatohepatitis (NASH). The company's management will present at three key investor conferences: the SVB Securities Global Biopharma Conference on February 14, Cowen Annual Healthcare Conference on March 6, and the Oppenheimer Annual Healthcare Conference on March 13, 2023. Each presentation will be available via webcast, and recordings will be archived on Madrigal’s website. Madrigal’s lead candidate, resmetirom, is designed to address significant unmet needs in NASH.

CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor conferences:

SVB Securities Global Biopharma Conference
4:20 pm ET on Tuesday, February 14, 2023.

Cowen Annual Healthcare Conference
2:50 pm ET on Monday, March 6, 2023.

Oppenheimer Annual Healthcare Conference
10:40 am ET on Monday, March 13, 2023.

The presentations will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

FAQ

What are the upcoming investor conferences for Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals will participate in the SVB Securities Global Biopharma Conference on February 14, Cowen Annual Healthcare Conference on March 6, and Oppenheimer Annual Healthcare Conference on March 13, 2023.

When will Madrigal Pharmaceuticals present at the SVB Securities Global Biopharma Conference?

Madrigal Pharmaceuticals will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 4:20 pm ET.

How can I access the presentations made by Madrigal Pharmaceuticals at the investor conferences?

The presentations will be webcast and archived recordings will be available for replay on Madrigal Pharmaceuticals' Investors section of their website.

What is Madrigal Pharmaceuticals' lead candidate for treating NASH?

Madrigal Pharmaceuticals' lead candidate for treating NASH is resmetirom, a once daily oral thyroid hormone receptor (THR)-β selective agonist.

Why is NASH a focus for Madrigal Pharmaceuticals (MDGL)?

NASH is a liver disease with a high unmet medical need, making it a critical focus for Madrigal Pharmaceuticals' therapeutic development.